Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1

Pediatric Infectious Disease Journal

Volumn 22, Issue 1, 2003, Pages 48-55

  Litalien, Catherine ^a   Faye, Albert ^a   Compagnucci, Alexandra ^b   Giaquinto, Carlo ^c   Harper, Lynda ^d   Gibb, Diana M ^d   Jacqz Aigrain, Evelyne ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b INSERM   (France)

^c UNIVERSITY OF PADOVA   (Italy)

^d MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Childe; Human immunodeficiency virus type 1; Infants; M8 metabolite; Nelfinavir; Pharmacokinetics; Protease inhibitor

Indexed keywords

HYDROXY TERT BUTYLAMIDE; NELFINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; FEMALE; FIRST PASS EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MASS SPECTROMETRY; PERINATAL INFECTION; PRIORITY JOURNAL; VERTICAL TRANSMISSION;

DIDANOSINE; DISEASE TRANSMISSION, VERTICAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; MALE; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; STAVUDINE;

EID: 0037236245     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200301000-00014     Document Type: Article

References (32)

1. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in pediatric HIV infection. December 14, 2001. Available from: http://www.hivatis.org.
2. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1: Women and Infants Transmission Study Group. N Engl J Med 1997;336:1337-42.
3. Luzuriaga K, McManus M, Catalina M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 2000;74:6984-91.
4. Clendeninn N, Quart B, Anderson R, Knowles M, Chang Y, for the Viracept Cooperative Study Group, Agouron Pharmaceuticals SD, CA. Analysis of long-term virologic data from the VIRACEPT (nelfinavir, NFV) 511 protocol using 3 HIV-RNA assays [Abstract 372]. In: Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1 to 5, 1998:148.
5. Henry K, Lamarca A, Myers R, Chapman S, for the Viracept Collaborative Study Group, Agouron Pharmaceuticals LJ, Ca. The safety of Viracept® (nelfinavir mesylate, NFV) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with either d4T or AZT/3TC [Abstract 384]. In: Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22 to 26, 1997:108.
6. Clumeck N, Group. AS. AVANTI 3: a randomized double blind comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs. AZT/3TC/nelfinavir in antiretroviral naive patients [Abstract 8]. In: Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1 to 5, 1998:80.
7. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999;28:1109-18.
8. Wiznia A, Stanley K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy- experienced HIV-infected children: Week 24 results of a randomized controlled trial - PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. AIDS Res Hum Retroviruses 2000;16:1113-21.
9. Haubrich R, Kemper C, Witt M. Differences in protease inhibitor (PI) phenotypic susceptibility after failure of the first PI-containing regimen [Abstract 1167]. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26 to 29, 1999. Washington, DC: American Society for Microbiology, 1999:493.
10. Brundage RC, Fletcher CV, Fenton T, et al. Efavirenz (EFV) and nelfinavir (NFV) pharmacokinetics (PK) in HIV-infected children under 2 years of age [Abstract 719]. In: Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30 to February 2, 2000:209.
11. Funk MB, Linde R, Wintergerst U, et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS 1999;13:1653-8.
12. Schuster T, Linde R, Wintergerst U, et al. Nelfinavir pharmacokinetics in HIV-infected children: a comparison of twice daily and three times daily dosing. Aids 2000;14:1466-8.
13. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1: Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 1999;341:1874-81.
14. van Heeswijk RP, Scherpbier HJ, Van Leeuwen MC, Hoetelmans RM, Lange JM. Steady-state pharmacokinetics of nelfinavir mesylate (NFV; Viracept) in HIV-infected children [Abstract 42274]. In: Twelfth World AIDS Conference, Geneva, June 26 to July 2, 1998:828.
15. Hayashi S, Wiznia A, Jaywardene A, et al. Nelfinavir pharmacokinetics in stable HIV positive children; the effect of weight and a comparison of BID to TID dosing [Abstract 427]. In: Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1 to 5, 1999:148.
16. Capparelli EV, Sullivan JL, Mofenson L, et al. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. Pediatr Infect Dis J 2001;20:746-51.
17. CAP, Inc. Product information: Viracept (nelfinavir). La Jolla: CAP, Inc., 2000.
18. Zhang K, Wu E, Patick A. Plasma metabolites of nelfinavir, a potent HIV protease inhibitor, in HIV positive patients: quantification by LC-MS/MS and antiviral activities [Abstract 128]. In: Sixth European ISSX Meeting, Gothenburg, June 5 to 9, 1997:128.
19. Munsiff AV, Razaq M. Twice daily nelfinavir results in more durable suppression than TID dosing [Abstract]. In: Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30 to February 5, 2000.
20. Markowitz M, Conant M, Hurley A, et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998;177:1533-40.
21. Lillibridge JH, Lee CA, Pithavala YK, et al. The role of polymorphic CYPC19 in the metabolism of nelfinavir mesylate [Abstract 3035]. In: Twelfth American Association of Pharmaceutical Scientists Annual Meeting and Exposition, San Francisco, November 15 to 19, 1998.
22. Patick AK, Mo H, Markowitz M, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996;40:292-7.
23. Molla A, Vasavanonda S, Kumar G, et al. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998;250:255-62.
24. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999;13:1873-80.
25. Khaliq Y, Gallicano K, Seguin I, et al. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. Br J Clin Pharmacol 2000;50:108-15.
26. Kerr B, Pithavala Y, Zhang M, Knowles M, Daniels R, Anderson R. Virologic response-plasma drug concentration relationship in Phase III study of nelfinavir mesylate (Viracept®] [Abstract 12304]. In: Twelfth World AIDS Conference, Geneva, June 26 to July 2, 1998:73.
27. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285-99.
28. Kearns GL. Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes? Curr Opin Pediatr 1995;7:220-33.
29. Johnson TN, Tanner MS, Taylor CJ, Tucker GT. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol 2001;51:451-60.
30. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver: evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997;247:625-34.
31. Mahmood B, Daood MJ, Hart C, Hansen TW, Watchko JF. Ontogeny of P-glycoprotein in mouse intestine, liver, and kidney. J Invest Med 2001;49:250-7.
32. Litalien C, Faye A, Ciaquinto C, et al. Abstract 2609. In: Pediatric Academic Societies 2001 Annual Meeting, Baltimore, MD, April 28 to May 1, 2001.